Literature DB >> 12911719

Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma.

B Melichar1, C A Savary, R Patenia, S Templin, K Melicharova, R S Freedman.   

Abstract

Monocytes/macrophages (MO/MA) represent a major leukocyte population in the peritoneal cavity of patients with epithelial ovarian cancer (EOC). We examined the phenotypic characteristics and antitumor cell activity of ascitic MO in patients with EOC. MO/MA phenotype was compared with MO in peripheral blood by two- and three-color flow cytometry. Cytotoxic/cytostatic effects of different cytokines on cultured EOC cells were measured by initial labeling or uptake inhibition of [methyl-3H] thymidine. Malignant ascites had higher proportion of MO/MA with the CD14brightCD16+ phenotype than peripheral blood. Cell surface antigen expression of activation and differentiation in peripheral blood and ascites, including CD38, CD40, CD64, and CD86, was higher on CD14brightCD16- and CD14brightCD16+ than on CD14dimCD16- cells. HLA-DR expression was higher on ascitic MO/MA than peripheral blood MO. Significant cytotoxic/cytostatic activity was elicited by treating ascitic MO/MA with interferon-gamma (IFN-gamma) and interleukin-2 (IL-2), but not with interleukin-12, paclitaxel, granulocyte-monocyte colony-stimulating factor (GM-CSF), or tumor necrosis factor-alpha (TNF-alpha). Soluble CD40Lt did not enhance MO/MA cytotoxic activity, and inhibited IFN-gamma or IL-2 induced cytoxicity. We conclude that MO/MA from ascites have elevated proportions of CD14brightCD16+ cells, showing phenotypic features of activation. IFN-gamma induces the cytotoxic and cytostatic activity of MO/MA that is inhibited by CD40Lt.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911719     DOI: 10.1046/j.1525-1438.2003.13331.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

Review 1.  Neopterin as a biomarker of immune response in cancer patients.

Authors:  Bohuslav Melichar; Martina Spisarová; Marie Bartoušková; Lenka Kujovská Krčmová; Lenka Javorská; Hana Študentová
Journal:  Ann Transl Med       Date:  2017-07

2.  A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.

Authors:  Kathleen M Schmeler; Saroj Vadhan-Raj; Pedro T Ramirez; Sachin M Apte; Lorenzo Cohen; Roland L Bassett; Revathy B Iyer; Judith K Wolf; Charles L Levenback; David M Gershenson; Ralph S Freedman
Journal:  Gynecol Oncol       Date:  2009-03-04       Impact factor: 5.482

3.  Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin.

Authors:  Sachin M Apte; Saroj Vadhan-Raj; Lorenzo Cohen; Roland L Bassett; Ilyssa O Gordon; Charles F Levenback; Pedro T Ramirez; Stacie T Gallardo; Rebecca S Patenia; Michael E Garcia; Revathy B Iyer; Ralph S Freedman
Journal:  J Transl Med       Date:  2006-04-07       Impact factor: 5.531

4.  A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.

Authors:  Meiying Zhang; Yifeng He; Xiangjun Sun; Qing Li; Wenjing Wang; Aimin Zhao; Wen Di
Journal:  J Ovarian Res       Date:  2014-02-08       Impact factor: 4.234

5.  Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer.

Authors:  Esma Karkeni; Stéphanie O Morin; Berna Bou Tayeh; Armelle Goubard; Emmanuelle Josselin; Rémy Castellano; Cyril Fauriat; Geoffrey Guittard; Daniel Olive; Jacques A Nunès
Journal:  Front Immunol       Date:  2019-06-06       Impact factor: 7.561

6.  Trends in peritoneal surface malignancies: evidence from a Czech nationwide population-based study.

Authors:  Dušan Klos; Juraj Riško; Martin Loveček; Pavel Skalický; Ivana Svobodová; Denisa Krejčí; Bohuslav Melichar; Beatrice Mohelníková-Duchoňová; Radmila Lemstrová
Journal:  World J Surg Oncol       Date:  2019-11-06       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.